-
EP2152308
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2152308
| EP2152308 - NEW INDICATIONS FOR ANTI- IL-I-BETA THERAPY [Right-click to bookmark this link] | Status | The application has been refused Status updated on 29.03.2019 Database last updated on 14.03.2026 | Most recent event Tooltip | 29.03.2019 | Refusal of application | published on 01.05.2019 [2019/18] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2010/07] | Inventor(s) | 01 /
GRAM, Hermann Am Bischofsacker 20 79576 Weil Am Rhein / DE | 02 /
JUNG, Thomas Leegasse 5/12 A-1140 Wien / AT | [2010/07] | Representative(s) | Carpmaels & Ransford LLP, et al One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2010/07] | Masselink, Johannes Hendrikus Bernardus, et al Novartis Pharma AG Patent Department 4002 Basel / CH | Application number, filing date | 08760116.7 | 28.05.2008 | [2010/07] | WO2008EP56520 | Priority number, date | EP20070109084 | 29.05.2007 Original published format: EP 07109084 | [2010/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2008145664 | Date: | 04.12.2008 | Language: | EN | [2008/49] | Type: | A1 Application with search report | No.: | EP2152308 | Date: | 17.02.2010 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.12.2008 takes the place of the publication of the European patent application. | [2010/07] | Search report(s) | International search report - published on: | EP | 04.12.2008 | Classification | IPC: | A61K39/395, C07K16/24, A61P37/06, C07K14/545 | [2010/07] | CPC: |
C07K16/245 (EP,KR,US);
A61K39/395 (RU);
A61K39/3955 (US);
A61P17/00 (EP);
A61P19/02 (EP);
A61P29/00 (EP,KR);
A61P37/00 (EP,KR,RU);
A61P37/02 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61K2039/505 (KR,US);
C07K2317/21 (US);
C07K2317/565 (US);
C07K2317/76 (EP,KR,US);
C07K2317/92 (EP,KR,US)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/07] | Title | German: | NEUE ANZEIGEN FÜR EINE ANTI-IL-I-BETA-THERAPIE | [2010/07] | English: | NEW INDICATIONS FOR ANTI- IL-I-BETA THERAPY | [2010/07] | French: | NOUVELLES INDICATIONS POUR UNE THÉRAPIE ANTI-IL-I-BÊTA | [2010/07] | Entry into regional phase | 29.12.2009 | National basic fee paid | 29.12.2009 | Designation fee(s) paid | 29.12.2009 | Examination fee paid | Examination procedure | 29.12.2009 | Examination requested [2010/07] | 17.02.2010 | Amendment by applicant (claims and/or description) | 09.03.2010 | Despatch of a communication from the examining division (Time limit: M06) | 09.09.2010 | Reply to a communication from the examining division | 12.10.2010 | Despatch of a communication from the examining division (Time limit: M04) | 16.02.2011 | Reply to a communication from the examining division | 24.05.2011 | Despatch of a communication from the examining division (Time limit: M06) | 11.01.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 29.02.2012 | Reply to a communication from the examining division | 10.10.2012 | Date of oral proceedings | 24.10.2012 | Minutes of oral proceedings despatched | 03.01.2013 | Despatch of communication that the application is refused, reason: substantive examination [2019/18] | 09.02.2018 | Application refused, date of legal effect [2019/18] | Appeal following examination | 07.03.2013 | Appeal received No. T1317/13 | 08.05.2013 | Statement of grounds filed | 09.02.2018 | Result of appeal procedure: appeal of the applicant was rejected | 09.02.2018 | Date of oral proceedings | 20.02.2018 | Minutes of oral proceedings despatched | Divisional application(s) | EP12158373.6 / EP2468301 | EP12158424.7 / EP2468302 | EP18177247.6 / EP3406263 | EP22196860.5 / EP4177268 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.03.2010 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 29.02.2012 | Request for further processing filed | 29.02.2012 | Full payment received (date of receipt of payment) Request granted | 16.03.2012 | Decision despatched | Fees paid | Renewal fee | 31.03.2010 | Renewal fee patent year 03 | 11.05.2011 | Renewal fee patent year 04 | 30.03.2012 | Renewal fee patent year 05 | 10.05.2013 | Renewal fee patent year 06 | 31.03.2014 | Renewal fee patent year 07 | 12.05.2015 | Renewal fee patent year 08 | 10.05.2016 | Renewal fee patent year 09 | 10.05.2017 | Renewal fee patent year 10 | 11.05.2018 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] WO2007050607 (NOVARTIS AG et al.) [X] 1-9 * sequences 1,2 * * examples 1-3 * * claims 1-9 * * page 14, line 29 - line 34 * | [X] WO2005082070 (BAYLOR RES INST et al.) [X] 1-3,7,9 * example 2 * | [A] WO2007042524 (NOVO NORDISK AS et al.) [A] * claims 1-18 * | [A] WO2005000215 (UNIV COLORADO REGENTS et al.) [A] * examples 1-17 * | [X] HOFFMAN ET AL: "The First Placebo-Controlled Trial in Cryopyrin-Associated Periodic Syndromes (CAPS): IL-1 Trap (rilonacept) Markedly Reduces Clinical and Laboratory Abnormalities in Patients with Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 119, no. 2, February 2007 (2007-02-01), pages 524, XP005874020, ISSN: 0091-6749 [X] 1-3,7-9 * the whole document * DOI: http://dx.doi.org/10.1016/j.jaci.2006.12.631 | [A] SO ALEXANDER ET AL: "A pilot study of IL-1 inhibition by anakinra in acute gout", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 2, 12 March 2007 (2007-03-12), pages R28, XP021026972, ISSN: 1478-6354 [A] * the whole document * DOI: http://dx.doi.org/10.1186/ar2143 | Examination | SO ALEXANDER ET AL: "A pilot study of IL-1 inhibition by anakinra in acute gout", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB LNKD- DOI:10.1186/AR2143, vol. 9, no. 2, 12 March 2007 (2007-03-12), pages R28, XP021026972, ISSN: 1478-6354 DOI: http://dx.doi.org/10.1186/ar2143 | MARTINON FABIO ET AL: "Gout-associated uric acid crystals activate the NALP3 inflammasome", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/NATURE04516, vol. 440, no. 7081, 9 March 2006 (2006-03-09), pages 237 - 241, XP002430440, ISSN: 0028-0836 DOI: http://dx.doi.org/10.1038/nature04516 | DI GIOVINE F S ET AL: "Interleukin 1 (IL 1) as a mediator of crystal arthritis. stimulation of T cell and Synovial Fibroblast mitogenesis by urate Crystal-induced IL 1", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 138, no. 10, 15 May 1987 (1987-05-15), pages 3213 - 3218, XP002494438, ISSN: 0022-1767 | CHEN CHUN-JEN ET AL: "MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.", THE JOURNAL OF CLINICAL INVESTIGATION AUG 2006 LNKD- PUBMED:16886064, vol. 116, no. 8, August 2006 (2006-08-01), pages 2262 - 2271, ISSN: 0021-9738 |